Averting inflammation by targeting the cytokine environment

Nature Reviews Drug Discovery

Volumn 9, Issue 9, 2010, Pages 703-718

  Kopf, Manfred ^a   Bachmann, Martin F ^b   Marsland, Benjamin J ^a  

^a ETH ZURICH   (Switzerland)

^b CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ADALIMUMAB; AIN 457; ALD 518; AMG 317; AMG 811; AMG 827; CANAKINUMAB; CERTOLIZUMAB PEGOL; CNTO 136; CNTO 328; CYTOKINE; ETANERCEPT; FEZAKINUMAB; GAMMA INTERFERON; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROACETEMRA; SIMPONI; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ASTHMA; AUTOIMMUNITY; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CINCA SYNDROME; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENTERITIS; GOUT; HUMAN; IMMUNOREGULATION; INFECTION CONTROL; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; ANIMAL; CHRONIC DISEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CHRONIC DISEASE; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION;

EID: 77956326466     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2805     Document Type: Review

References (212)

1. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258-267 (1957).
2. Isaacs, A., Lindenmann, J. & Valentine, R. C. Virus interference. II. Some properties of interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 268-273 (1957).
3. Simmons, D. L. What makes a good anti-inflammatory drug target? Drug Discov. Today 11, 210-219 (2006).
4. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594-1602 (2000).
5. Elliott, M. J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36, 1681-1690 (1993).
6. Moreland, L. W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147 (1997).
7. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor-inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
8. Powrie, F. et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1, 553-562 (1994).
9. Kojouharoff, G. et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 107, 353-358 (1997).
10. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F. & Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
11. Kosiewicz, M. M. et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohns disease. J. Clin. Invest. 107, 695-702 (2001).
12. Neurath, M. F. et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27, 1743-1750 (1997).
13. Mori, L., Iselin, S., De Libero, G. & Lesslauer, W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 157, 3178-3182 (1996).
14. Liu, J. et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Med. 4, 78-83 (1998).
15. Targan, S. R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohns disease. N. Engl. J. Med. 337, 1029-1035 (1997).
16. Leonardi, C. L. et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
17. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 457-465 (1999).
18. ten Hove, T., van Montfrans, C., Peppelenbosch, M. P. & van Deventer, S. J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohns disease. Gut 50, 206-211 (2002).
19. Carswell, E. A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666-3670 (1975).
20. Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas; with a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1893).
21. van Horssen, R., Ten Hagen, T. L. & Eggermont, A. M. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397-408 (2006).
22. Prevost-Blondel, A., Roth, E., Rosenthal, F. M. & Pircher, H. Crucial role of TNF-α in CD8 T cellmediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J. Immunol. 164, 3645-3651 (2000).
23. Calzascia, T. et al. TNF-α is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 117, 3833-3845 (2007).
24. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006).
25. Bongartz, T. et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 68, 1177-1183 (2009).
26. Askling, J. et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor-therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 60, 3180-3189 (2009).
27. Smedby, K. E., Askling, J., Mariette, X. & Baecklund, E. Autoimmune and inflammatory disorders and risk of malignant lymphomas - an update. J. Intern. Med. 264, 514-527 (2008).
28. Askling, J. et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann. Rheum. Dis. 68, 648-653 (2009).
29. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K. & Sethi, G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72, 1605-1621 (2006).
30. Moore, R. J. et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med. 5, 828-831 (1999).
31. Suganuma, M. et al. Essential role of tumor necrosis factor α (TNF- α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res. 59, 4516-4518 (1999).
32. Knight, B. et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 192, 1809-1818 (2000).
33. Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
34. Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466 (2004).
35. Wallis, R. S., Broder, M., Wong, J. & Beenhouwer, D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 39, 1254-1255 (2004).
36. Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E. & Beenhouwer, D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261-1265 (2004).
37. Spohn, G. et al. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 38, 877-887 (2008).
38. Wallis, R. S., Broder, M., Wong, J., Lee, A. & Hoq, L. Reactivation of latent granulomatous infections by infliximab. Clin. Infect. Dis. 41 (Suppl. 3), 194-198 (2005).
39. Howard, K. A. et al. Chitosan/siRNA nanoparticlemediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther. 17, 162-168 (2009).
40. Schiffelers, R. M., Xu, J., Storm, G., Woodle, M. C. & Scaria, P. V. Effects of treatment with small interfering RNA on joint inflammation in mice with collageninduced arthritis. Arthritis Rheum. 52, 1314-1318 (2005).
41. Horiuchi, K. et al. Cutting edge: TNF-α-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J. Immunol. 179, 2686-2689 (2007).
42. Moss, M. L., Sklair-Tavron, L. & Nudelman, R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nature Clin. Pract Rheumatol. 4, 300-309 (2008).
43. Thabet, M. M. & Huizinga, T. W. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr. Opin. Investig. Drugs 7, 1014-1019 (2006).
44. Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281-1284 (1998).
45. Kishimoto, T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
46. Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339-342 (1994).
47. Dalrymple, S. A. et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect. Immun. 63, 2262-2268 (1995).
48. Ladel, C. H. et al. Lethal tuberculosis in interleukin-6- deficient mutant mice. Infect. Immun. 65, 4843-4849 (1997).
49. Suzuki, Y. et al. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect. Immun. 65, 2339-2345 (1997).
50. Romani, L. et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183, 1345-1355 (1996).
51. Eugster, H. P., Frei, K., Kopf, M., Lassmann, H. & Fontana, A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 28, 2178-2187 (1998).
52. Samoilova, E. B., Horton, J. L., Hilliard, B., Liu, T. S. & Chen, Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161, 6480-6486 (1998).
53. Ohshima, S. et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl Acad. Sci. USA 95, 8222-8226 (1998).
54. Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468 (1998).
55. Eriksson, U. et al. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 107, 320-325 (2003).
56. Hata, H. et al. Distinct contribution of IL-6, TNF-α, IL-1 and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 114, 582-588 (2004).
57. Yamamoto, M., Yoshizaki, K., Kishimoto, T. & Ito, H. IL-6 is required for the development of Th1 cellmediated murine colitis. J. Immunol. 164, 4878-4882 (2000).
58. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature Med. 6, 583-588 (2000).
59. Hirano, T. et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18, 1797 - 1801 (1988).
60. Grossman, R. M. et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl Acad. Sci. USA 86, 6367-6371 (1989).
61. Gross, V., Andus, T., Caesar, I., Roth, M. & Scholmerich, J. Evidence for continuous stimulation of interleukin-6 production in Crohns disease. Gastroenterology 102, 514-519 (1992).
62. Mitsuyama, K. et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36, 45-49 (1995).
63. Trikha, M., Corringham, R., Klein, B. & Rossi, J. F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9, 4653-4665 (2003).
64. van Zaanen, H. C. et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J. Clin. Invest. 98, 1441-1448 (1996).
65. van Zaanen, H. C. et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol. 102, 783-790 (1998).
66. Nishimoto, N. et al. Improvement in Castlemans disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56-61 (2000).
67. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial. Lancet 371, 987-997 (2008).
68. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
69. Jones, G. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69, 88-96 (2010).
70. Yokota, S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 371, 998-1006 (2008).
71. Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160-167 (2001).
72. Nowell, M. A. et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182, 613-622 (2009).
73. Ohtaki, H. et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc. Natl Acad. Sci. USA 103, 7488-7493 (2006).
74. Yamashita, T. et al. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J. Neurochem. 94, 459-468 (2005).
75. Cressman, D. E. et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379-1383 (1996).
76. Hong, F. et al. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins. Oncogene 21, 32-43 (2002).
77. Klein, C. et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J. Clin. Invest. 115, 860-869 (2005).
78. Kovalovich, K. et al. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 31, 149-159 (2000).
79. Hansen, M. B., Svenson, M., Diamant, M. & Bendtzen, K. Anti-interleukin-6 antibodies in normal human serum. Scand. J. Immunol. 33, 777-781 (1991).
80. Homann, C. et al. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. Scand. J. Immunol. 44, 623-629 (1996).
81. Dinarello, C. A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16, 457-499 (1998).
82. Agostini, L. et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325 (2004).
83. Neven, B. et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS and FCU. Blood 103, 2809-2815 (2004).
84. Hawkins, P. N., Bybee, A., Aganna, E. & McDermott, M. F. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 50, 2708-2709 (2004).
85. Hawkins, P. N., Lachmann, H. J., Aganna, E. & McDermott, M. F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50, 607-612 (2004).
86. Lovell, D. J., Bowyer, S. L. & Solinger, A. M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283-1286 (2005).
87. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425 (2009).
88. Goldbach-Mansky, R. et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 58, 2432-2442 (2008).
89. Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrinassociated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452 (2008).
90. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).
91. Terkeltaub, R. et al. The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann. Rheum. Dis. 26 Jul 2009 (doi:10.1136/ard.2009.108936).
92. Shi, Y., Evans, J. E. & Rock, K. L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521 (2003).
93. Chen, C. J. et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 116, 2262-2271 (2006).
94. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
95. Matsuki, T., Nakae, S., Sudo, K., Horai, R. & Iwakura, Y. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 18, 399-407 (2006).
96. Eriksson, U. et al. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J. Exp. Med. 197, 323-331 (2003).
97. Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF α, anti-IL-1 α/β, and IL-1Ra. Arthritis Rheum. 39, 797-809 (1996).
98. Palmer, G. et al. Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis. Eur. J. Immunol. 33, 434-440 (2003).
99. Mertens, M. & Singh, J. A. Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol, 36, 1118-1125 (2009).
100. Ikonomidis, I. et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117, 2662-2669 (2008).
101. Matsuki, T. et al. Involvement of tumor necrosis factor-α in the development of T cell-dependent aortitis in interleukin-1 receptor antagonist-deficient mice. Circulation 112, 1323-1331 (2005).
102. Sutton, C., Brereton, C., Keogh, B., Mills, K. H. & Lavelle, E. C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685-1691 (2006).
103. Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479-1486 (2005).
104. Matsuki, T., Horai, R., Sudo, K. & Iwakura, Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. 198, 877-888 (2003).
105. Larsen, C. M. et al. Interleukin1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
106. Lust, J. A. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1βinduced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84, 114-122 (2009).
107. Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity. Nature Rev. Immunol. 8, 533-544 (2008).
108. Hamilton, J. A. Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slowacting anti-rheumatic drugs. Lancet 342, 536-539 (1993).
109. Sonderegger, I. et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 205, 2281-2294 (2008).
110. Campbell, I. K. et al. Protection from collagen-induced arthritis in granulocyte-macrophage colonystimulating factor-deficient mice. J. Immunol. 161, 3639-3644 (1998).
111. McQualter, J. L. et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 194, 873-882 (2001).
112. Sainathan, S. K. et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm. Bowel Dis. 14, 88-99 (2008).
113. Dieckgraefe, B. K. & Korzenik, J. R. Treatment of active Crohns disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360, 1478-1480 (2002).
114. Korzenik, J. R., Dieckgraefe, B. K., Valentine, J. F., Hausman, D. F. & Gilbert, M. J. Sargramostim for active Crohns disease. N. Engl. J. Med. 352, 2193-2201 (2005).
115. Antman, K. S. et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Engl. J. Med. 319, 593-598 (1988).
116. Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003).
117. Murphy, C. A. et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003).
118. Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310-1316 (2006).
119. Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005).
120. Becher, B., Durell, B. G. & Noelle, R. J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 110, 493-497 (2002).
121. Eriksson, U., Kurrer, M. O., Sebald, W., Brombacher, F. & Kopf, M. Dual role of the IL-12/IFN-α axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-α. J. Immunol. 167, 5464-5469 (2001).
122. Willenborg, D. O., Fordham, S., Bernard, C. C., Cowden, W. B. & Ramshaw, I. A. IFN-α plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157, 3223-3227 (1996).
123. Bettelli, E., Oukka, M. & Kuchroo, V. K. TH-17 cells in the circle of immunity and autoimmunity. Nature Immunol. 8, 345-350 (2007).
124. McGeachy, M. J. & Cua, D. J. Th17 cell differentiation: the long and winding road. Immunity 28, 445-453 (2008).
125. Ouyang, W., Kolls, J. K. & Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28, 454-467 (2008).
126. Haak, S. et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 119, 61-69 (2009).
127. Kreymborg, K. et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J. Immunol. 179, 8098-8104 (2007).
128. Sonderegger, I., Kisielow, J., Meier, R., King, C. & Kopf, M. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur. J. Immunol. 38, 1833-1838 (2008).
129. Coquet, J. M., Chakravarti, S., Smyth, M. J. & Godfrey, D. I. Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J. Immunol. 180, 7097-7101 (2008).
130. Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273-290 (2007).
131. Burton, P. R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genet. 39, 1329-1337 (2007).
132. Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
133. Silverberg, M. S. et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nature Genet. 41, 216-220 (2009).
134. Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008).
135. Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).
136. Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633-640 (2009).
137. Sandborn, W. J. et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohns disease. Gastroenterology 135, 1130-1141 (2008).
138. Segal, B. M. et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796-804 (2008).
139. Jouanguy, E. et al. IL-12 and IFN-α in host defense against mycobacteria and salmonella in mice and men. Curr. Opin. Immunol. 11, 346-351 (1999).
140. Chackerian, A. A. et al. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect. Immun. 74, 6092-6099 (2006).
141. Cooper, A. M., Magram, J., Ferrante, J. & Orme, I. M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J. Exp. Med. 186, 39-45 (1997).
142. Zelante, T. et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur. J. Immunol. 37, 2695-2706 (2007).
143. Abbas, A. K., Murphy, K. M. & Sher, A. Functional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
144. Sigidin, Y. A., Loukina, G. V., Skurkovich, B. & Skurkovich, S. Randomized, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis. Scand. J. Rheumatol. 30, 203-207 (2001).
145. Hommes, D. W. et al. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohns disease. Gut 55, 1131-1137 (2006).
146. Guedez, Y. B. et al. Genetic ablation of interferon-γ up-regulates interleukin-1β expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum. 44, 2413-2424 (2001).
147. Camoglio, L. et al. Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-α receptor-deficient mice. Eur. J. Immunol. 30, 1486-1495 (2000).
148. Steinman, L. A rush to judgment on Th17. J. Exp. Med. 205, 1517-1522 (2008).
149. Casanova, J. L. & Abel, L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20, 581-620 (2002).
150. Weaver, C. T., Hatton, R. D., Mangan, P. R. & Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25, 821-852 (2007).
151. Chang, S. H. & Dong, C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 17, 435-440 (2007).
152. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485-517 (2009).
153. Khader, S. A., Gaffen, S. L. & Kolls, J. K. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2, 403-411 (2009).
154. Ishigame, H. et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30, 108-119 (2009).
155. Genovese, M. et al. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum. 62, 929-939 (2010).
156. Tak, P. et al. AIN457 shows a good safety profile and clinical benefit in patients with active rheumatoid arthritis (RA) despite methotrexate therapy: 16-weeks results from a randomized proof-of-concept trial. Arthritis Rheum. 60 (Suppl. 10), 1922 (2009).
157. Zheng, Y. et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648-651 (2007).
158. Kolls, J. K., McCray, P. B. Jr & Chan, Y. R. Cytokine-mediated regulation of antimicrobial proteins. Nature Rev. Immunol. 8, 829-835 (2008).
159. Sanos, S. L. et al. ROR-t and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nature Immunol. 10, 83-91 (2009).
160. Satoh-Takayama, N. et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29, 958-970 (2008).
161. Cella, M. et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722-725 (2009).
162. Zenewicz, L. A. et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29, 947-957 (2008).
163. Sugimoto, K. et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118, 534-544 (2008).
164. Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033-2045 (2009).
165. Zenewicz, L. A. et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27, 647-659 (2007).
166. Aujla, S. J. et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nature Med. 14, 275-281 (2008).
167. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature Med. 14, 282-289 (2008).
168. Leonard, W. J. & Spolski, R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nature Rev. Immunol. 5, 688-698 (2005).
169. Spolski, R. & Leonard, W. J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26, 57-79 (2008).
170. Parrish-Novak, J. et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57-63 (2000).
171. Yang, L. et al. IL-21 and TGF-α are required for differentiation of human TH17 cells. Nature 454, 350-352 (2008).
172. Korn, T. et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448, 484-487 (2007).
173. Nurieva, R. et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480-483 (2007).
174. Frohlich, A. et al. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 109, 2023-2031 (2007).
175. Nurieva, R. I. et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29, 138-149 (2008).
176. Vogelzang, A. et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29, 127-137 (2008).
177. Linterman, M. A. et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 207, 353-363 (2010).
178. Bessa, J., Kopf, M. & Bachmann, M. F. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J. Immunol. 184, 4615-4619 (2010).
179. Sawalha, A. H. et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann. Rheum. Dis. 67, 458-461 (2008).
180. Herber, D. et al. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 178, 3822-3830 (2007).
181. King, C., Tangye, S. G. & Mackay, C. R. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu. Rev. Immunol. 26, 741-766 (2008).
182. Fort, M. M. et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15, 985-995 (2001).
183. Owyang, A. M. et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J. Exp. Med. 203, 843-849 (2006).
184. Fallon, P. G. et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med. 203, 1105-1116 (2006).
185. Lee, J. et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J. Biol. Chem. 276, 1660-1664 (2001).
186. Rickel, E. A. et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol. 181, 4299-4310 (2008).
187. Tamachi, T. et al. IL-25 enhances allergic airway inflammation by
188. Ballantyne, S. J. et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol. 120, 1324-1331 (2007).
189. Kleinschek, M. A. et al. IL-25 regulates Th17 function in autoimmune inflammation. J. Exp. Med. 204, 161-170 (2007).
190. Liu, Y. J. et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu. Rev. Immunol. 25, 193-219 (2007).
191. Zhou, B. et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nature Immunol. 6, 1047-1053 (2005).
192. Ito, T. et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202, 1213-1223 (2005).
193. Yoo, J. et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J. Exp. Med. 202, 541-549 (2005).
194. Soumelis, V. et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nature Immunol. 3, 673-680 (2002).
195. Al-Shami, A., Spolski, R., Kelly, J., Keane-Myers, A. & Leonard, W. J. A role for TSLP in the development of inflammation in an asthma model. J. Exp. Med. 202, 829-839 (2005).
196. Allakhverdi, Z. et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 204, 253-258 (2007).
197. Taylor, B. C. et al. TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J. Exp. Med. 206, 655-667 (2009).
198. Cohn, L., Elias, J. A. & Chupp, G. L. Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 22, 789-815 (2004).
199. Cohn, L., Homer, R. J., Marinov, A., Rankin, J. & Bottomly, K. Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J. Exp. Med. 186, 1737-1747 (1997).
200. Borish, L. C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963-970 (2001).
201. Borish, L. C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebocontrolled trial. Am. J. Respir. Crit. Care Med. 160, 1816-1823 (1999).
202. Steinke, J. W. & Borish, L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir. Res. 2, 66-70 (2001).
203. Leckie, M. J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356, 2144-2148 (2000).
204. Kips, J. C. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167, 1655-1659 (2003).
205. Plotz, S. G. et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N. Engl. J. Med. 349, 2334-2339 (2003).
206. Nair, P. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985-993 (2009).
207. Jennings, G. T. & Bachmann, M. F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu. Rev. Pharmacol. Toxicol. 49, 303-326 (2009).
208. Rohn, T. A. et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36, 2857-2867 (2006).
209. Sonderegger, I. et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol. 36, 2849-2856 (2006).
210. Spohn, G. et al. A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 178, 7450-7457 (2007).
211. Yu, D. & Vinuesa, C. G. Multiple checkpoints keep follicular helper T cells under control to prevent autoimmunity. Cell. Mol. Immunol. 7, 198-203 (2010).
212. Omori, M. & Ziegler, S. Induction of IL-4 expression in CD4+ T cells by thymic stromal lymphopoietin. J. Immunol. 178, 1396-1404 (2007).